Search
Semaglutide Treatment Options for Obesity
A collection of 77 research studies in Obesity where Semaglutide is the interventional treatment. Semaglutide is used for conditions such as Obesity.
73 - 77 of 77
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Psoriasis & Overweight Clinical Study
Recruiting
Have you tried different treatments for psoriasis while also managing your weight? Are you:
- Diagnosed with plaque psoriasis
- Struggling with weight management
- at least 18 years old
A clinical trial may be an option for you. Learn more about the TOGETHER-PsO study and see if you may be eligible to participate.
- Diagnosed with plaque psoriasis
- Struggling with weight management
- at least 18 years old
A clinical trial may be an option for you. Learn more about the TOGETHER-PsO study and see if you may be eligible to participate.
Conditions:
Overweight
Overweight and Obesity
Obesity
Psoriasis
Plaque Psoriasis
Featured Trial
Psoriasis & Overweight Clinical Study
Recruiting
Have you tried different treatments for psoriasis while also managing your weight? Are you:
- Diagnosed with plaque psoriasis
- Struggling with weight management
- at least 18 years old
A clinical trial may be an option for you. Learn more about the TOGETHER-PsO study and see if you may be eligible to participate.
- Diagnosed with plaque psoriasis
- Struggling with weight management
- at least 18 years old
A clinical trial may be an option for you. Learn more about the TOGETHER-PsO study and see if you may be eligible to participate.
Conditions:
Overweight
Overweight and Obesity
Obesity
Morbid Obesity
Obesity
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
Completed
This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. Together with the medicine, the participant will also be part of an intensive lifestyle program where the participant will have talks with study staff about healthy food choices, what the participant can do to lose weight and be more physically active. The participant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/10/2021
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +40 locations
Conditions: Overweight, Obesity
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
Completed
This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the study medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what else the participant can do to lose weight. Overweight and obesity is associated with an increased risk... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2021
Locations: Novo Nordisk Investigational Site, Buena Park, California +146 locations
Conditions: Obesity, Overweight
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
Completed
The study is investigating new medicines for weight control in people with high body weight. The study looks at how the study medicines work in the body. Participants will get semaglutide and either NNC0165-1562 or "dummy" medicine -which treatment participants get is decided by chance. Participants will get 2 injections per week for 5 months. A study nurse at the clinic will inject the medicine with a thin needle in a skin fold in the stomach. The study will last for about 7 months. Participant... Read More
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
07/01/2021
Locations: Novo Nordisk Investigational Site, Tempe, Arizona +1 locations
Conditions: Metabolism and Nutrition Disorders, Overweight or Obesity
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
Completed
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2020
Locations: Novo Nordisk Investigational Site, Anaheim, California +73 locations
Conditions: Metabolism and Nutrition Disorder, Obesity
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
Completed
The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts. If participants take part in Part 1, they will either get a single dose of NNC0165-1875 or a "dummy" medicine (placebo). If participants take part in Part 2, they will either get a single dose of NNC0165-1875 or "dummy" medicine and also a single dose of semaglutide. Which treatment participants get is decid... Read More
Gender:
MALE
Ages:
All
Trial Updated:
09/05/2019
Locations: Novo Nordisk Investigational Site, Tempe, Arizona
Conditions: Obesity and Overweight
73 - 77 of 77